Four months af­ter im­ple­ment­ing new PhI­II safe­ty pro­to­col, or­gan trans­plant biotech re­ports pa­tient death

A Boston biotech look­ing to make or­gan trans­plants less dan­ger­ous is find­ing it­self in the midst of a se­ri­ous neg­a­tive pa­tient out­come.

An in­di­vid­ual died in a Phase III study from Ta­laris Ther­a­peu­tics, the com­pa­ny an­nounced Thurs­day, suc­cumb­ing af­ter de­vel­op­ing symp­toms as­so­ci­at­ed with acute graft-ver­sus-host dis­ease. Though Ta­laris did not re­port whether the death was re­lat­ed to its ex­per­i­men­tal drug, the biotech’s da­ta mon­i­tor­ing com­mit­tee said the study can con­tin­ue dos­ing and new pa­tient en­roll­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER